期刊
JOURNAL OF CLINICAL NEUROSCIENCE
卷 28, 期 -, 页码 185-186出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2015.12.004
关键词
Biomarker; Gaucher; GBA; GBA enzyme activity; Glucocerebrosidase; Parkinson's disease
资金
- Bigglesworth Family Foundation
- Empire State Clinical Research Training Program
- Marcled Foundation
- NIH-NINDS [NS073836, NS094148]
Mutations in the glucocerebrosidase (GBA1) gene, the most common genetic contributor to Parkinson's disease (PD), are associated with an increased risk of PD in heterozygous and homozygous carriers. While glucocerebrosidase enzyme (GCase) activity is consistently low in Gaucher disease, there is a range of leukocyte GCase activity in healthy heterozygous GBA1 mutation carriers. To determine whether GCase activity may be a marker for PD with heterozygous GBA1 mutations (GBA1 mutation PD, GBA PD), GM PD patients (n = 15) were compared to PD patients without heterozygous GBA1 mutations (idiopathic PD; n = 8), heterozygous GBA1 carriers without PD (asymptomatic carriers; n = 4), and biallelic mutation carriers with PD (Gaucher disease with PD, GD1 PD; n = 3) in a pilot study. GCase activity (nmol/mg protein/hour) in GD1 PD (median [interquartile range]; minimum maximum: 6.4 [5.7]; 5.3-11) was lower than that of GBA PD (16.0 [7.0]; 11-40) (p = 0.01), while GCase activity in GBA PD was lower than idiopathic PD (28.5 [15.0]; 16-56) (p = 0.01) and asymptomatic carriers (25.5 [2.5]; 23-27) (p = 0.04). Therefore, GCase activity appears to be a possible marker of heterozygous GBA1 mutation PD, and larger studies are warranted. Prospective studies are also necessary to determine whether lower GCase activity precedes development of PD. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据